MHS552

MHS552 is a biological investigational drug developed by Novartis for the treatment of autoimmune diseases, primarily systemic lupus erythematosus (SLE) and type 1 diabetes mellitus. Its precise mechanism of action has not been disclosed or remains undefined. The drug was administered subcutaneously in clinical trials as a multiple ascending dose regimen to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with mild to moderate SLE and adults with type 1 diabetes mellitus. Clinical development included phase 1 studies in both indications but was terminated or withdrawn before completion due to sponsor decisions. No serious adverse events were reported during the trials; common side effects included injection site reactions such as swelling, itching, pain, erythema, headache, and COVID-19 infection[1][2][3][4][5][7].